These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 23293055)
21. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. Yu C; Chen S; Guo Y; Sun C Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725 [No Abstract] [Full Text] [Related]
22. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Park JK; Lee EJ; Esau C; Schmittgen TD Pancreas; 2009 Oct; 38(7):e190-9. PubMed ID: 19730150 [TBL] [Abstract][Full Text] [Related]
23. In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS- Mediated Signalling Pathways. Wu W; Xia Q; Luo RJ; Lin ZQ; Xue P Asian Pac J Cancer Prev; 2015; 16(10):4369-76. PubMed ID: 26028101 [TBL] [Abstract][Full Text] [Related]
24. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. Fryer RA; Barlett B; Galustian C; Dalgleish AG Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196 [TBL] [Abstract][Full Text] [Related]
26. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003 [TBL] [Abstract][Full Text] [Related]
27. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Mittal A; Chitkara D; Behrman SW; Mahato RI Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261 [TBL] [Abstract][Full Text] [Related]
30. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877 [TBL] [Abstract][Full Text] [Related]
31. Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells. Huang CC; Lin CM; Huang YJ; Wei L; Ting LL; Kuo CC; Hsu C; Chiou JF; Wu ATH; Lee WH Biotechnol Appl Biochem; 2017 Mar; 64(2):165-173. PubMed ID: 26400206 [TBL] [Abstract][Full Text] [Related]
32. Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB. Liu A; Chen H; Tong H; Ye S; Qiu M; Wang Z; Tan W; Liu J; Lin S Mol Med Rep; 2011; 4(2):221-7. PubMed ID: 21468555 [TBL] [Abstract][Full Text] [Related]
33. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920 [TBL] [Abstract][Full Text] [Related]
34. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914 [TBL] [Abstract][Full Text] [Related]
35. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
36. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. Pandita A; Kumar B; Manvati S; Vaishnavi S; Singh SK; Bamezai RN PLoS One; 2014; 9(9):e107154. PubMed ID: 25197966 [TBL] [Abstract][Full Text] [Related]
37. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015 [TBL] [Abstract][Full Text] [Related]
38. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Dong J; Zhao YP; Zhou L; Zhang TP; Chen G Arch Med Res; 2011 Jan; 42(1):8-14. PubMed ID: 21376256 [TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970 [TBL] [Abstract][Full Text] [Related]
40. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]